Nuvation Bio Inc. has provided an update on its oncology pipeline and commercial activities. The company highlighted the approval of IBTROZI (taletrectinib), a next-generation ROS1 inhibitor, for advanced ROS1-positive non-small cell lung cancer (NSCLC) in the United States, Japan, and China. As of September 30, 2025, 204 patients in the U.S. have started treatment with IBTROZI in the third quarter, and confirmed payor coverage extends to 80% of eligible lives. Nuvation Bio also reported progress on its clinical and preclinical programs, including safusidenib, which is entering a pivotal study for high-grade IDH1-mutant glioma, and NUV-868, a BD2-selective BET inhibitor that has completed Phase 1 and 1b studies. The company continues to evaluate additional candidates from its proprietary Drug-Drug Conjugate $(DDC)$ platform. Nuvation Bio reported a cash balance of $549 million as of September 30, 2025, with further funding available under an existing loan facility. You can access the full presentation through the link below.